Effects of different sera on adipose tissue-derived mesenchymal stromal cells

Journal of Tissue Engineering and Regenerative Medicine

Volumn 5, Issue 9, 2011, Pages 733-746

  Tunaitis, Virginijus ^a   Borutinskaite, Veronika ^b   Navakauskiene, Ruta ^b   Treigyte, Gražina ^b   Unguryte, Aušra ^a   Aldonyte, Ruta ^a   Magnusson, Karl Eric ^c   Pivoriunas, Augustas ^a  

^a State Research Institute Center for Innovative Medicine   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Adipose tissue; Differentiation marker; Mesenchymal stromal cell; Regenerative medicine; Serum substitute; Tissue engineering

Indexed keywords

BODY FLUIDS; CELL CULTURE; CELL ENGINEERING; FLOWCHARTING; GENE EXPRESSION; POLYMERASE CHAIN REACTION; REGENERATIVE MEDICINE; TISSUE;

ADIPOSE TISSUE; CELL THERAPY; CURRENT CELLS; DIFFERENTIATION MARKERS; FOETAL CALF SERUMS; MESENCHYMAL STROMAL CELLS; PROTEOMICS; REGENERATIVE MEDICINE; SERUM SUBSTITUTES; TISSUES ENGINEERINGS;

TISSUE ENGINEERING;

5' NUCLEOTIDASE; ALPHA ENOLASE; ALPHA TUBULIN; AXIN 1; BETA ACTIN; BETA TUBULIN; CD14 ANTIGEN; CD146 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; GAMMA TAXILIN; GLUCOSE REGULATED PROTEIN 94; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 70 8; HEAT SHOCK PROTEIN 90; LEUCINE RICH PPR MOTIF; LIPOCORTIN 2; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN F2 RECEPTOR; PROTEIN; PYRUVATE KINASE M1 M2; SERPIN BETA9; THY 1 ANTIGEN; TIOREDOXIN DOMAIN CONT PROTEIN; TRANSCRIPTION FACTOR MSX2; UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME 1; ULTROSER G; UNCLASSIFIED DRUG; VIMENTIN;

ADIPOGENESIS; ADIPOSE TISSUE; ADULT; AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; BONE DEVELOPMENT; BREAST; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; FETAL CALF SERUM; GENE EXPRESSION; HUMAN; HUMAN ALLOGENIC SERUM; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; IN VITRO STUDY; INTRAABDOMINAL FAT; MESENCHYMAL STROMAL CELL; MESENCHYME CELL; PRETESTED FETAL CALF SERUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; SERUM; STROMA CELL;

EID: 80053134688     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.374     Document Type: Article

References (47)

1. Agata H, Watanabe N, Ishii Y, et al. 2009; Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. Biochem Biophys Res Commun 382(2): 353-358.
2. Bianco P, Robey PG, Simmons PJ. 2008; Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2(4): 313-319.
3. Bodine PV, Komm BS. 2006; Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 7(1-2): 33-39.
4. Caplan AI. 2007; Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213(2): 341-347.
5. Caplan AI. 2009; Why are MSCs therapeutic? New data: new insight. J Pathol 217(2): 318-324.
6. Chachques JC, Herreros J, Trainini J, et al. 2004; Autologous human serum for cell culture avoids the implantation of cardioverter-defibrillators in cellular cardiomyoplasty. Int J Cardiol 95(suppl 1): S29-33.
7. Cheng SL, Shao JS, Charlton-Kachigian N, et al. 2003; Msx2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 278(46): 45969-45977.
8. Cock TA, Houten SM, Auwerx J. 2004; Peroxisome proliferator-activated receptor-γ: too much of a good thing causes harm. EMBO Rep 5(2): 142-147.
9. Crisan M, Yap S, Casteilla L, et al. 2008; A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3): 301-313.
10. da Silva Meirelles L, Caplan AI, Nardi NB. 2008; In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26(9): 2287-2299.
11. da Silva Meirelles L, Chagastelles PC, Nardi NB. 2006; Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119(Pt 11): 2204-2213.
12. Gregory CA, Reyes E, Whitney MJ, et al. 2006; Enhanced engraftment of mesenchymal stem cells in a cutaneous wound model by culture in allogenic species-specific serum and administration in fibrin constructs. Stem Cells 24(10): 2232-2243.
13. Halme DG, Kessler DA. 2006; Fda regulation of stem-cell-based therapies. N Engl J Med 355(16): 1730-1735.
14. Hirst J, Bright NA, Rous B, et al. 1999; Characterization of a fourth adaptor-related protein complex. Mol Biol Cell 10(8): 2787-2802.
15. Hong JH, Hwang ES, McManus MT, et al. 2005; Taz, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309(5737): 1074-1078.
16. Ichida F, Nishimura R, Hata K, et al. 2004; Reciprocal roles of msx2 in regulation of osteoblast and adipocyte differentiation. J Biol Chem 279(32): 34015-34022.
17. Jung J, Moon N, Ahn JY, et al. 2009; Mesenchymal stromal cells expanded in human allogenic cord blood serum display higher self-renewal and enhanced osteogenic potential. Stem Cells Dev 18(4): 559-571.
18. Korhonen M. 2007; Culture of human mesenchymal stem cells in serum-free conditions: no breakthroughs yet. Eur J Haematol 78(2): 167; author reply, 168.
19. Kuznetsov SA, Mankani MH, Robey PG. 2000; Effect of serum on human bone marrow stromal cells: ex vivo expansion and in vivo bone formation. Transplantation 70(12): 1780-1787.
20. Lee RH, Pulin AA, Seo MJ, et al. 2009; Intravenous HMSCS improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein tsg-6. Cell Stem Cell 5(1): 54-63.
21. Liu C-H, Wu M-L, Hwang S-M. 2007; Optimization of serum-free medium for cord blood mesenchymal stem cells. Biochem Eng J 33(1): 1-9.
22. t) method. Methods 25(4): 402-408.
23. Logan CY, Nusse R. 2004; The wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810.
24. Mannello F, Tonti GA. 2007; Concise review. No breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells 25(7): 1603-1609.
25. Meuleman N, Tondreau T, Delforge A, et al. 2006; Human marrow mesenchymal stem cell culture: serum-free medium allows better expansion than classical α-MEM medium. Eur J Haematol 76(4): 309-316.
26. Oga T, Matsuoka T, Yao C, et al. 2009; Prostaglandin f2α receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-β. Nat Med 15(12): 1426-1430.
27. Oprea GE, Krober S, McWhorter ML, et al. 2008; Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320(5875): 524-527.
28. Orlicky DJ, Berry R, Sikela JM. 1996; Human chromosome 1 localization of the gene for a prostaglandin f2α receptor negative regulatory protein. Hum Genet 97(5): 655-658.
29. Phinney DG, Prockop DJ. 2007; Concise review. Mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 25(11): 2896-2902.
30. Rangaswami H, Bulbule A, Kundu GC. 2006; Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2): 79-87.
31. Ryoo HM, Hoffmann HM, Beumer T, et al. 1997; Stage-specific expression of dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression. Mol Endocrinol 11(11): 1681-1694.
32. Sacchetti B, Funari A, Michienzi S, et al. 2007; Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131(2): 324-336.
33. Samar B. 2007; Novel cyclooxygenase-catalyzed bioactive prostaglandin f2 from physiology to new principles in inflammation. Med Res Rev 27(4): 435-468.
34. Satokata I, Ma L, Ohshima H, et al. 2000; Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 24(4): 391-395.
35. Selvaggi TA, Walker RE, Fleisher TA. 1997; Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 89(3): 776-779.
36. Shahdadfar A, Fronsdal K, Haug T, et al. 2005; In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 23(9): 1357-1366.
37. Shevchenko A, Chernushevic I, Wilm M, et al. 2002; 'De novo' sequencing of peptides recovered from in-gel digested proteins by nanoelectrospray tandem mass spectrometry. Mol Biotechnol 20(1): 107-118.
38. Shevchenko A, Wilm M, Vorm O, et al. 1996; Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68(5): 850-858.
39. Sirard C, Kim S, Mirtsos C, et al. 2000; Targeted disruption in murine cells reveals variable requirement for smad4 in transforming growth factor-β-related signaling. J Biol Chem 275(3): 2063-2070.
40. Spees JL, Gregory CA, Singh H, et al. 2004; Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 9(5): 747-756.
41. Stipp CS, Orlicky D, Hemler ME. 2001; Fprp, a major, highly stoichiometric, highly specific cd81- and cd9-associated protein. J Biol Chem 276(7): 4853-4862.
42. Takada I, Mihara M, Suzawa M, et al. 2007; A histone lysine methyltransferase activated by non-canonical wnt signalling suppresses PPAR-γ transactivation. Nat Cell Biol 9(11): 1273-1285.
43. Takada I, Suzawa M, Kato S. 2005; Nuclear receptors as targets for drug development: crosstalk between peroxisome proliferator-activated receptor-γ and cytokines in bone marrow-derived mesenchymal stem cells. J Pharmacol Sci 97(2): 184-189.
44. Tuschong L, Soenen SL, Blaese RM, et al. 2002; Immune response to fetal calf serum by two adenosine deaminase-deficient patients after t cell gene therapy. Hum Gene Ther 13(13): 1605-1610.
45. Wan Y, Chong LW, Evans RM. 2007; Ppar-gamma regulates osteoclastogenesis in mice. Nat Med 13(12): 1496-1503.
46. Yu HM, Jerchow B, Sheu TJ, et al. 2005; The role of axin2 in calvarial morphogenesis and craniosynostosis. Development 132(8): 1995-2005.
47. Zannettino AC, Paton S, Arthur A, et al. 2008; Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. J Cell Physiol 214(2): 413-421.